Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 6/20 | 0.55 |
| ▸ | NPY1R | P25929 | 3/20 | 0.53 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.53 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.53 |
| ▸ | NPY4R | P50391 | 2/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | GNRHR | P30968 | 1/20 | 0.51 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.51 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423100 | 0.89 | APLNR (0.45) | OPRD1NPY1RNMUR2NMUR1NPY4R | |
| SCHEMBL29619531 | 0.88 | NPY4R (0.58) | NPY1RNMUR2NMUR1NPY4RNPY2R | |
| SCHEMBL5499951 | 0.83 | NPY4R (0.58) | NPY1RNMUR2NMUR1NPY4RNPY2R | |
| SCHEMBL32670190 | 0.83 | OPRK1 (0.61) | OPRD1NMUR2NMUR1OPRK1GNRHR | |
| SCHEMBL29590609 | 0.82 | APLNR (0.42) | NPY1RNMUR2NMUR1GNRHRNTSR2 | |
| SCHEMBL29390426 | 0.81 | OPRM1 (0.61) | NPY1RNMUR2NMUR1NPY4RNPY2R | |
| SCHEMBL8808129 | 0.80 | NMUR2 (0.70) | NMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL8808113 | 0.80 | NMUR2 (0.70) | NMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL30943512 | 0.80 | NTSR2 (0.56) | OPRD1NPY1RNMUR2NMUR1NPY4R | |
| SCHEMBL29479234 | 0.79 | NTSR1 (0.66) | OPRD1NPY1RNMUR2NMUR1NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109170-A1 | METHOD FOR MANUFACTURING GANIRELIX | ANYGEN CO., LTD. (KR) | 2025-04-03 | — | — | US | disclosed |
| WO-2023101490-A1 | NOVEL METHOD FOR MANUFACTURING GANIRELIX | 애니젠 주식회사 | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109170-A1 | METHOD FOR MANUFACTURING GANIRELIX | VIP, GLP1R, CCKBR | OPRD1 2619/4885NPY1R 168/4885NMUR2 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.